You just read:

Petra Pharma Presents Preclinical PIP4K2 Inhibitor Data as a Potential Treatment for Hematologic Malignancies at the 2018 American Society of Hematology Annual Meeting

News provided by

Petra Pharma Corporation

Dec 01, 2018, 17:00 ET